HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.

Abstract
Disopyramide was administered intravenously to 54 patients during atrial fibrillation and predominantly pre-excited QRS configuration at the time of electrophysiologic study. All patients had Wolff-Parkinson-White syndrome and no patient had coexistent heart disease. The drug was given during sustained atrial fibrillation (n = 45) or during sinus rhythm before induction of atrial fibrillation for patients whose atrial fibrillation was self-terminating in the control state (n = 9). Atrial fibrillation converted to sinus rhythm within 15 min after disopyramide in 37 (82%) of the 45 patients. The shortest RR intervals between two pre-excited cycles increased from 208 +/- 42 to 293 +/- 117 ms (p less than 0.0001). The average RR interval of all cycles prolonged from 332 +/- 60 to 396 +/- 117 ms(n = 45, p less than 0.0001). The 9 patients in whom pre-excitation was abolished after the drug had a significantly longer initial shortest RR interval than that of the 36 patients in whom pre-excitation persisted (246 +/- 47 versus 199 +/- 36 ms, p = 0.0022). No patients developed significant hemodynamic or other adverse effects after disopyramide. These data support the intravenous use of disopyramide in patients with normal ventricular function who have atrial fibrillation and a predominant ventricular response over an accessory atrioventricular pathway.
AuthorsO Fujimura, G J Klein, A D Sharma, R Yee, T Szabo
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 13 Issue 5 Pg. 1133-7 (Apr 1989) ISSN: 0735-1097 [Print] United States
PMID2926064 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Disopyramide
Topics
  • Adolescent
  • Adult
  • Atrial Fibrillation (complications, drug therapy, physiopathology)
  • Disopyramide (therapeutic use)
  • Electrocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Time Factors
  • Wolff-Parkinson-White Syndrome (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: